CA2784768C - Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia - Google Patents

Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia Download PDF

Info

Publication number
CA2784768C
CA2784768C CA2784768A CA2784768A CA2784768C CA 2784768 C CA2784768 C CA 2784768C CA 2784768 A CA2784768 A CA 2784768A CA 2784768 A CA2784768 A CA 2784768A CA 2784768 C CA2784768 C CA 2784768C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2784768A
Other languages
English (en)
French (fr)
Other versions
CA2784768A1 (en
Inventor
Lourdes Prieto
Lorena Taboada Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2784768A1 publication Critical patent/CA2784768A1/en
Application granted granted Critical
Publication of CA2784768C publication Critical patent/CA2784768C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2784768A 2009-12-29 2010-12-21 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia Expired - Fee Related CA2784768C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382309.4 2009-12-29
EP09382309 2009-12-29
US30793510P 2010-02-25 2010-02-25
US61/307,935 2010-02-25
PCT/US2010/061406 WO2011082010A1 (en) 2009-12-29 2010-12-21 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
CA2784768A1 CA2784768A1 (en) 2011-07-07
CA2784768C true CA2784768C (en) 2015-02-03

Family

ID=42029907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784768A Expired - Fee Related CA2784768C (en) 2009-12-29 2010-12-21 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia

Country Status (6)

Country Link
US (1) US8592590B2 (de)
EP (1) EP2519521B1 (de)
JP (1) JP5775094B2 (de)
CA (1) CA2784768C (de)
ES (1) ES2443578T3 (de)
WO (1) WO2011082010A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4637578B2 (ja) 2002-08-09 2011-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2556263A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE402935T1 (de) * 2004-02-18 2008-08-15 Astrazeneca Ab Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
ES2627688T3 (es) * 2010-04-02 2017-07-31 Ogeda Sa Novedosos compuestos antagonistas selectivos del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por los receptores de NK-3

Also Published As

Publication number Publication date
EP2519521B1 (de) 2013-11-20
ES2443578T3 (es) 2014-02-19
WO2011082010A1 (en) 2011-07-07
US8592590B2 (en) 2013-11-26
CA2784768A1 (en) 2011-07-07
US20120252838A1 (en) 2012-10-04
JP2013515777A (ja) 2013-05-09
EP2519521A1 (de) 2012-11-07
JP5775094B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
CA2784768C (en) Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
JP6866535B2 (ja) アミノ酸化合物および使用方法
US20230117605A1 (en) Dosage forms and regimens for amino acid compounds
JP7179015B2 (ja) Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
JP2024037954A (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
CA2849751C (en) Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof
US20080153846A1 (en) Aminomethyl Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
JP2010500999A (ja) ベータ−セクレターゼの阻害剤としてのイミダゾールアミン
JP7248256B2 (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
JP2002105085A (ja) 新規イミダゾチアゾール誘導体
US20180362522A1 (en) Inhibiting agents for bruton's tyrosine kinase
IL206353A (en) (e) –n– (5 - (e) –3– fluorine –6 h– dibenzo [e, b] oxypane – 11 – indigenylmethyl) –1 - ((r) –1– methyl – 2 – morpholine – 4– Yl-ethyl) -3,1-dihydro-benzoimidazole-2-natal) -orea
IL266962A (en) Troyilphenoxide Benzamide Capaide Opioids Legends, Preparations Containing Them and Their Uses
JP6876625B2 (ja) Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物
CN111201234A (zh) 新型化合物及其作为acc抑制剂的用途
WO2017200857A1 (en) Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
WO2015066697A1 (en) Fused morpholinopyrimidines and methods of use thereof
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
CN117642416A (zh) 分拣蛋白活性调节剂
JPH08231521A (ja) ２−アミノ− １，３− チアゼピン及びこれを一酸化窒素合成酵素の阻害物質として使用する方法
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
WO2013186666A1 (en) Tricyclic compounds as kat ii inhibitors
AU2016211827A1 (en) Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
CA2989982C (en) Imidazodiazepine compound
WO2023187677A1 (en) N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181221